

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



August 8, 2025

Consolidated Financial Results for the Three Months Ended June 30, 2025 (Under Japanese GAAP)

Company name: Nomura Micro Science Co., Ltd.
 Listing: Tokyo Stock Exchange
 Securities code: 6254
 URL: <https://www.nomura-nms.co.jp/english>
 Representative: Makoto Uchida, President, Executive Officer
 Inquiries: Shiro Nishimura, Director, Executive Officer, General Manager of Management Head Office
 TEL: +81-46-228-5195
 Scheduled date to commence dividend payments: -
 Preparation of supplementary material on financial results: Yes
 Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated Financial Results for the Three Months of the Fiscal Year Ending March 31, 2026 (from April 01, 2025 to June 30, 2025)

(1) Consolidated operating results (Cumulative)

(Percentage indicate YoY changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Three months ended June 30, 2025	12,403	62.6	1,378	280.8	782	58.3	464	12.9
June 30, 2024	7,629	(40.2)	362	(78.2)	494	(76.4)	411	(63.2)

(Note) Comprehensive income For the three months ended March 31, 2026: 131 million yen ((90.9)%) For the three months ended March 31, 2025: 1,455 million yen ((13.4)%)

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Three months ended June 30, 2025	12.27	12.11
June 30, 2024	10.95	10.62

(2) Consolidated financial positions

	Total assets	Net assets	Equity-to-assets ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
As of June 30, 2025	103,874	34,950	33.1	906.86
March 31, 2025	116,783	37,013	31.2	963.39

(Reference) Owner's equity As of the first quarter of the fiscal year ending March 2026: 34,338 million yen As of the fiscal year ended March 2025: 36,476 million yen

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	-	20.00	-	60.00	80.00
Fiscal year ending March 31, 2026	-				
Fiscal year ending March 31, 2026 (Forecast)		20.00	-	50.00	70.00

(Note) Presence or absence of revisions to the most recently announced dividend forecast: None

3. Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2026 (from April 01, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net Sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending September 30, 2025	24,500	35.8	2,115	36.2	1,114	-	825	-	21.79
Fiscal year ending March 31, 2026	60,000	(37.7)	6,200	(59.7)	5,184	(61.3)	3,837	(62.4)	101.33

(Note) Correction of financial forecast from the most recent financial forecast: None

Basic earnings per share for the second quarter (cumulative) and the full fiscal year ending March 2026 are calculated based on the average number of shares, which is determined using the number of treasury shares at the end of the first quarter.

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies (company names) -, Excluded: - companies (company names) -

(2) Application of specific accounting for the consolidated quarterly financial statements: Yes

(Note) For details, please refer to page 8 of the attached materials, "2. Quarterly Consolidated Financial Statements and Main Notes (3) Notes on Quarterly Consolidated Financial Statements (Notes on Accounting Treatments Specific to the Preparation of Quarterly Consolidated Financial Statements)."

(3) Changes in accounting policies, changes in accounting estimates, retrospective restatement

(i) Changes in accounting policies due to revisions of accounting standards and other regulations : None

(ii) Changes in accounting policies other than (i): None

(iii) Changes in accounting estimates : None

(iv) Restatement : None

(4) Number of shares issued (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2025	40,608,000 shares
As of March 31, 2025	40,608,000 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2025	2,742,939 shares
As of March 31, 2025	2,744,939 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2025	37,863,728 shares
Three months ended June 30, 2024	37,534,216 shares

※ Review of attached consolidated quarterly financial statements by a certified public accountant or an audit firm: None

Note: Explanation regarding the appropriate use of forecasts and other special notes

The forward-looking statements such as performance forecasts contained in this document are based on information currently available to the Company and on certain assumptions that are deemed reasonable. They are not intended as a guarantee of achievement by the Company. Actual results may differ significantly due to various factors. For the conditions underlying the forecasts and notes on the use of forecasts, please refer to the attached document, page 3, "1. Overview of operating results, etc. (3) Explanation regarding consolidated forecasts and other forward-looking information."

Attached Material Index

Index

1. Overview of Operating Results	2
(1) Overview of Operating Results for the Three Months Ended June 30, 2025	2
(2) Overview of Financial Position for the Three Months Ended June 30, 2025	3
(3) Explanation of Consolidated Earnings Forecast and Other Forward-Looking Statements	3
2. Quarterly Consolidated Financial Statements and Significant Notes Thereto	4
(1) Quarterly Consolidated Balance Sheets	4
(2) Quarterly Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	6
(3) Notes to Quarterly Consolidated Financial Statements	8
(Notes on Special Accounting Methods for Preparing Quarterly Consolidated Financial Statements)	8
(Notes on Segment Information, etc.)	8
(Notes on Substantial Changes in the Amount of Shareholders' Equity)	9
(Notes on Going Concern Assumption)	9
(Notes on Quarterly Consolidated Statements of Cash Flows)	9
(Significant Subsequent Events)	10

1. Overview of Operating Results

(1) Overview of Operating Results for the Three Months Ended June 30, 2025

During the three months ended June 30, 2025, the global economy maintained solid growth; however, unstable conditions persisted due to increasing downside risks from U.S. tariff policies and the prolonged slowdown of the Chinese economy.

In the semiconductor industry, which affects the performance of our group, capital investment remained strong, driven by increased demand for generative AI and cloud infrastructure, leading to expanded investment in memory and logic finished goods. SEMI (Semiconductor Equipment and Materials International) announced that global semiconductor manufacturing equipment sales in the first quarter of 2025 reached USD 32.0 billion, a 21.0% increase compared to the same period of the previous year.

Under these circumstances, our group aims to increase corporate value and achieve the medium-term management plan "Together Toward Transformation 26 (TTT-26)" formulated in November 2023 by focusing on (1) improving profitability, (2) capital efficiency, (3) financial optimization, and shareholder returns, (4) creating social value. We have strengthened our approach to the semiconductor and pharmaceutical industries, reformed engineering processes, and implemented various measures to improve productivity and profitability while working toward the realization of sustainability management.

As a result, orders received were 4,402 million yen (down 42.0% YoY), net sales were 12,403 million yen (up 62.6% YoY), operating profit was 1,378 million yen (up 280.8% YoY), ordinary profit was 782 million yen (up 58.3% YoY), and profit attributable to owners of parent was 464 million yen (up 12.9% YoY).

(Orders received)

Although capital investment by semiconductor-related companies, which are our group's main customers, remains strong, orders have been concentrated in the second half of the fiscal year, resulting in a low level of orders received in the first quarter.

(Net sales)

Regarding water treatment equipment, net sales were 8,749 million yen (up 97.4% YoY), mainly due to the steady progress of construction for large-scale water treatment equipment already ordered in the United States and Japan. In addition, for maintenance and consumables, orders remained strong, particularly from semiconductor-related companies, resulting in net sales of 3,512 million yen (up 38.0% YoY). On the other hand, for other businesses, net sales were 141 million yen (down 78.3% YoY), mainly due to the completion of sales of piping materials for large semiconductor manufacturing equipment.

(Profit)

In terms of profit, operating profit and all subsequent profit levels exceeded those of the same period of the previous year, mainly due to increased revenue from steady progress in large-scale water treatment equipment projects in the United States and Japan, as well as projects in other regions.

Operating results by segment are as follows.

1.Japan

Due to the steady progress of construction for large-scale domestic water treatment equipment that had already been ordered, net sales reached 7,467 million yen (up 106.1% YoY). Operating profit was 763 million yen (compared to an operating loss of 9 million yen in the same period of the previous year), mainly due to the contribution of highly profitable large-scale projects, resulting in a significant increase in both sales and profit.

2.Korea

The construction of large-scale water treatment equipment ordered by the end of the previous fiscal year is expected to make significant progress in the second half and beyond, and as a result, net sales were at a low level in the first quarter, amounting to 611 million yen (down 41.6% YoY), and operating profit was 60 million yen (down 47.2% YoY).

3.China

While orders for maintenance and consumables remained steady, due to the completion of major water treatment equipment projects, net sales were 990 million yen (down 23.5% YoY), and operating profit was 9 million yen (down 53.4% YoY).

4.Taiwan

While construction of large-scale water treatment equipment has reached a temporary lull, orders for maintenance and consumables increased. As a result, net sales were 644 million yen (down 7.7% YoY), and operating profit was 187 million yen (up 8.0% YoY).

5.United States

Due to the smooth progress of construction for large-scale water treatment equipment that had already been ordered, net sales increased significantly to 2,682 million yen (up 177.7% YoY), and operating profit rose substantially to 361 million yen (up 462.4% YoY), resulting in a significant increase in both sales and profits.

6.Others

In the previous consolidated fiscal year, as part of our business strategy to realize the medium-term management plan "TTT-26" and in response to the diversification of semiconductor manufacturing bases, we established Nomura Micro Science Singapore Pte. Ltd. and included it within the scope of consolidation. Accordingly, we have added "Others" as a new reporting segment. Operations commenced in the first quarter, and net sales amounted to 6 million yen from orders for maintenance and consumables. However, due to the inability to fully absorb establishment costs and other expenses, an operating loss of 3 million yen was recorded.

Note: In the previous consolidated fiscal year, Nomura Micro Science Singapore Pte. Ltd. did not commence business operations, and therefore, there were no recorded net sales or operating profit/loss.

(2) Overview of Financial Position for the Three Months Ended June 30, 2025

As for total assets at the end of the first quarter of the consolidated fiscal period, they decreased by 12,908 million yen compared to the end of the previous consolidated fiscal year, amounting to 103,874 million yen. This was mainly due to an increase in work in process of 2,403 million yen and an increase in cash and deposits of 1,559 million yen, while notes and accounts receivable - trade, and contract assets decreased by 16,088 million yen, among other factors.

Total liabilities decreased by 10,845 million yen compared to the end of the previous consolidated fiscal year, amounting to 68,924 million yen. This was mainly due to a decrease of 4,684 million yen in short-term borrowings, a decrease of 4,161 million yen in notes and accounts payable - trade, and a decrease of 1,996 million yen in contract liabilities, among other factors.

Net assets decreased by 2,063 million yen compared to the end of the previous consolidated fiscal year, amounting to 34,950 million yen. This was mainly due to a decrease in retained earnings of 1,807 million yen and a decrease in foreign currency translation adjustment of 336 million yen, among other factors.

(3) Explanation of Consolidated Earnings Forecast and Other Forward-Looking Statements

There are no changes to the consolidated forecasts for the six months ending September 30, 2025 and the fiscal year ending March 31, 2026, which were announced on May 15, 2025

2. Quarterly Consolidated Financial Statements and Significant Notes Thereto
(1) Quarterly Consolidated Balance Sheet

(Thousands of yen)

	As of March 31,2025	As of June 30,2025
Assets		
Current assets		
Cash and deposit	17,330,150	18,889,697
Notes and accounts receivable - trade, and contract assets	82,339,287	66,251,027
Electronically recorded monetary claims - operating	2,534,590	1,300,629
Merchandise and finished goods	552,990	582,904
Work in process	2,009,656	4,413,069
Raw materials and supplies	1,159,077	1,036,596
Other	3,470,440	3,863,438
Allowance for doubtful accounts	(405,851)	(354,254)
Total current asset	108,990,341	95,983,109
Non-current assets		
Property, plant and equipment	4,957,867	4,871,137
Intangible assets	119,477	111,192
Investment other assets	2,715,454	2,908,700
Total non-current assets	7,792,798	7,891,031
Total assets	116,783,140	103,874,141
Liabilities		
Current liabilities		
Notes and accounts payable - trade	9,251,132	5,089,281
Short-term borrowings	52,158,200	47,473,850
Accounts payable - other	924,386	1,660,306
Income taxes payable	3,843,103	2,595,454
Contract liabilities	9,330,148	7,333,148
Provision for product warranties	241,844	347,780
Provision for bonuses	598,072	876,350
Provision for bonuses for directors	20,827	107,280
Asset retirement obligations	30,106	37,410
Other	2,496,807	2,664,815
Total current liabilities	78,894,628	68,185,677
Non-current liabilities		
Retirement benefit liability	10,121	10,609
Provision for retirement benefits for directors (and other officers)	222,226	218,708
Other	642,228	509,064
Total non-current liabilities	874,575	738,381
Total liabilities	79,769,204	68,924,059

(Thousands of yen)

	As of March 31,2025	As of June 30,2025
Net assets		
Shareholders' equity		
Share capital	2,236,800	2,236,800
Capital surplus	3,286,603	3,287,800
Retained earnings	29,736,483	27,929,101
Treasury shares	(330,121)	(329,880)
Total shareholders' equity	34,929,766	33,123,822
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	373,594	377,914
Foreign currency translation adjustment	1,173,591	836,607
Total accumulated other comprehensive income	1,547,185	1,214,521
Share acquisition rights	536,984	611,738
Total net assets	37,013,936	34,950,082
Total liabilities and net assets	116,783,140	103,874,141

(2) Quarterly Consolidated Statement of Income and Consolidated Statement of Comprehensive Income
(Quarterly Consolidated Statement of Income)

(Thousands of yen)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Net sales	7,629,109	12,403,144
Cost of sales	5,895,608	9,621,201
Gross profit	1,733,500	2,781,942
Selling, general and administrative expenses	1,371,475	1,403,394
Operating profit	362,025	1,378,548
Non-operating income		
Interest income	15,437	37,777
Dividend income	8,101	5,245
Rental income from buildings	7,175	8,053
Foreign exchange gains	472,936	-
Other	1,637	11,287
Total non-operating income	505,288	62,362
Non-operating expenses		
Interest expense	372,304	552,563
Other	509	105,647
Total non-operating expenses	372,813	658,210
Ordinary profit	494,500	782,700
Extraordinary income		
Gain on sale of investment securities	-	8,567
Total extraordinary income	-	8,567
Extraordinary losses		
Loss on retirement of fixed assets	3	0
Total extraordinary losses	3	0
Profit before income taxes	494,497	791,268
Income taxes	83,262	326,866
Profit	411,235	464,401
Profit attributable to owners of parent	411,235	464,401

(Quarterly Consolidated Statement of Comprehensive Income)

(Thousands of yen)

	Three months ended June 30, 2024	Three months ended June 30, 2025
Profit	411,235	464,401
Other comprehensive income		
Valuation difference on available-for-sale securities	70,336	4,319
Deferred gains or losses on hedges	29	-
Foreign currency translation adjustment	973,815	(336,983)
Total other comprehensive income	1,044,180	(332,663)
Comprehensive income	1,455,415	131,737
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	1,455,415	131,737

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on Special Accounting Methods for Preparing Quarterly Consolidated Financial Statements)

(Calculation of tax expenses)

With regard to income tax expenses, the effective tax rate after applying tax effect accounting to the pre-tax net income for the consolidated fiscal year including the first quarter of the current fiscal year is reasonably estimated, and the estimated effective tax rate is applied to the pre-tax net income to calculate the tax expenses.

Note that Income taxes - deferred are included in Income taxes.

(Notes on Segment Information, etc.)

I Previous first quarter consolidated cumulative period (from April 1, 2024 to June 30, 2024)

Information on amounts of Net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment						
	Japan	South Korea	China	Taiwan	United States of America	Other	Total
Net sales							
Net sales to external customers	3,623,111	1,046,582	1,294,928	698,449	966,037	-	7,629,109
Internal transactions between segments							
Net sales or transfer amount	612,118	189,534	44,253	-	29,408	-	875,316
Total	4,235,230	1,236,117	1,339,181	698,449	995,445	-	8,504,425
Segment profit or Loss (-)	(9,947)	114,501	19,430	173,818	64,223	-	362,025

	Adjustment amount	Amount recorded in quarterly consolidated statements of income (Note)
Net sales		
Net sales to external customers	-	7,629,109
Internal transactions between segments		
Net sales or transfer amount	(875,316)	-
Total	(875,316)	7,629,109
Segment profit or Loss (-)	-	362,025

(Note) Segment profit or loss is consistent with operating profit in the quarterly consolidated statement of income.

II For the three months ended June 30, 2025

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment						
	Japan	South Korea	China	Taiwan	United States of America	Other	Total
Net sales							
Net sales to external customers	7,467,044	611,640	990,293	644,844	2,682,614	6,706	12,403,144
Internal transactions between segments	446,123	88,242	1,867	-	-	-	536,234
Net sales or transfer amount							
Total	7,913,167	699,883	992,161	644,844	2,682,614	6,706	12,939,378
Segment profit or Loss (-)	763,455	60,446	9,057	187,687	361,197	(3,296)	1,378,548

	Adjustment amount	Amount recorded in quarterly consolidated statements of income (Note)
Net sales		
Net sales to external customers	-	12,403,144
Internal transactions between segments	(536,234)	-
Net sales or transfer amount		
Total	(536,234)	12,403,144
Segment profit or Loss (-)	-	1,378,548

(Note) Segment profit or loss is consistent with operating profit in the quarterly consolidated statement of income.

2. Matters related to changes in reportable segments

In the previous consolidated fiscal year, Nomura Micro Science Singapore Pte. Ltd. was newly established in Singapore and included within the scope of consolidation. As a result, "Others" has been added as a new reportable segment. Segment information for the previous first quarter consolidated cumulative period is disclosed based on the classification of reportable segments after the change.

(Notes on Substantial Changes in the Amount of Shareholders' Equity)

There are no applicable items.

(Notes on Going Concern Assumption)

There are no applicable matters.

(Notes on Quarterly Consolidated Statements of Cash Flows)

The quarterly consolidated statement of cash flows for the three months ended has not been prepared. Depreciation for the three months ended (including amortization of intangible assets) is as follows.

	For the three months ended [previous first quarter] (From April 1, 2024 As of June 30, 2024)	For the three months ended (From April 1, 2025 As of June 30, 2025)
Depreciation	93,287 thousand yen	564,475 thousand yen

(Notes on significant subsequent events)

(Issuance of share acquisition rights as stock options)

At the Board of Directors meeting held on August 8, 2025, the Company resolved to issue share acquisition rights as stock options to its executive officers (excluding those who concurrently serve as directors; hereinafter the same) and employees.

(1) Reason for issuing share acquisition rights as stock options

The purpose is to further strengthen the linkage between our business performance and stock value, and to enhance the motivation and morale of our executive officers and employees to contribute to the improvement of medium- to long-term business performance and corporate value.

(2) Outline of issuance of share acquisition rights

(i) Allottees of share acquisition rights

Our executive officers and employees

(ii) Type and number of shares subject to share acquisition rights

Up to 419,000 shares of the Company's common stock.

In the event that the Company conducts a stock split or reverse stock split, the number of shares to be acquired shall be adjusted according to the following formula. However, such adjustment shall be made only to the number of shares underlying the Share acquisition rights that have not been exercised at that time, and any fractional shares less than one share resulting from such adjustment shall be rounded down.

Adjusted number of shares = Number of shares before adjustment × Ratio of stock split or reverse stock split

(iii) Number of share acquisition rights

Up to a maximum of 4,190 units.

The number of shares to be acquired per share acquisition right (hereinafter referred to as the "Number of Granted Shares") shall be 100 shares. However, if an adjustment to the number of shares as stipulated in (ii) above is made, a similar adjustment shall be made accordingly.

(iv) Issuance of share acquisition rights value

No charge will be applied.

(v) Amount of assets to be contributed upon exercise of share acquisition rights

The amount of property to be contributed upon the exercise of share acquisition rights shall be the amount obtained by multiplying the exercise price per share (hereinafter referred to as the "exercise price") by the number of shares to be granted upon exercise of the share acquisition rights.

The exercise price shall be the higher of (i) the amount obtained by multiplying by 1.05 the average closing price of the Company's common stock in regular trading on the Tokyo Stock Exchange on each day of the month preceding the month to which the allotment date belongs (excluding days on which no trading is conducted; any fraction less than 1 yen shall be rounded up), or (ii) the closing price on the allotment date (or, if no trading is conducted on that date, the closing price on the most recent prior trading day). In the event that, after the allotment date of the share acquisition rights, the Company conducts a stock split or reverse stock split, the exercise price shall be adjusted in accordance with the following formula, with any fraction less than 1 yen resulting from the adjustment rounded up.

$$\text{Adjusted exercise price} = \frac{\text{Exercise price before adjustment}}{\text{Stock split/consolidation ratio}} \times \frac{1}{\text{Stock split/consolidation ratio}}$$

Also, after the allotment date of the Share acquisition rights, if the Company issues new shares of common stock or disposes of treasury shares at a price below market value, the exercise price shall be adjusted according to the following formula, and any fraction less than 1 yen resulting from the adjustment shall be rounded up.

$$\text{Adjusted exercise price} = \frac{\text{Exercise price before adjustment}}{\frac{\text{Number of shares issued} + \frac{\text{Number of newly issued shares} \times \text{Paid-in amount per share}}{\text{Market value}}}{\text{Number of shares already issued} + \text{number of newly issued shares}}}$$

(vi) Period during which share acquisition rights may be exercised

From September 24, 2027 to September 24, 2032

(vii) Conditions for the exercise of share acquisition rights

(i) Persons who have been allotted Share acquisition rights (hereinafter referred to as "Share acquisition rights holders") may exercise the Share acquisition rights only if, at the time of exercising such rights, they hold a position as a director, auditor, executive officer, employee, or any other equivalent position at the Company or its subsidiaries. However, in the event that a Share acquisition rights holder retires upon expiration of their term as a director or auditor of the Company or its subsidiaries, retires upon reaching the mandatory retirement age as an employee of the Company or its subsidiaries, or loses their position as a director, auditor, executive officer, employee, or any other equivalent position

at the Company or its subsidiaries due to a legitimate reason, they shall be entitled to exercise the Share acquisition rights.

If a Share acquisition rights holder dies before the expiration of the period during which the Share acquisition rights may be exercised, such rights shall be forfeited.

h The transfer, pledge, or any other disposition of all or part of the share acquisition rights shall not be permitted.

(2) Other conditions for the exercise of rights shall be as stipulated in the share acquisition rights allocation agreement to be concluded between the Company and the person to whom the share acquisition rights are allotted.

(viii) Restrictions on the transfer of share acquisition rights

The transfer of purchase of share acquisition rights requires the approval of the Board of Directors.

(ix) Matters concerning the increase in Share capital and Legal capital surplus in the case of issuing shares through the exercise of share acquisition rights

In the case of issuing shares through the exercise of share acquisition rights, the amount of increase in share capital shall be one-half of the maximum amount of increase in share capital, etc. calculated in accordance with Article 17, Paragraph 1 of the Ordinance on Company Accounting, and any fraction less than 1 yen resulting from the calculation shall be rounded up.

In the case where shares are issued through the exercise of share acquisition rights, the amount of increase in legal capital surplus shall be the amount obtained by deducting the amount of increase in share capital specified in (i) above from the maximum amount of increase in share capital, etc. stated in (i) above.